Healthscope’s plan to buy the diagnostics arm of Australian rival Symbion Health for A$1.6bn in shares collapsed Tuesday after the Australian tax office ruled the planned deal would not qualify for roll-over capital gains tax relief.

Symbion said that as a result of the ruling, neither the deal with Healthscope nor that with its private equity partners Ironbridge Capital and Archer Capital would proceed.